{
  "title": "Paper_163",
  "abstract": "pmc Nat Commun Nat Commun 2873 ncomms Nature Communications 2041-1723 Nature Publishing Group PMC12488948 PMC12488948.1 12488948 12488948 41034193 10.1038/s41467-025-63546-4 63546 1 Article Polygenic risk score for type 2 diabetes shows context-dependent effects across populations http://orcid.org/0000-0002-8508-4084 Guo Boya bguo@fredhutch.org 1 Cai Yanwei 1 http://orcid.org/0000-0002-9387-0739 Kim Daeeun 2 3 Smit Roelof A. J. 4 http://orcid.org/0000-0002-8046-4969 Wang Zhe 4 5 Iyer Kruthika R. 6 7 8 http://orcid.org/0000-0002-1289-4377 Hilliard Austin T. 8 Haessler Jeffrey 1 http://orcid.org/0000-0002-1106-2923 Tao Ran 9 10 Broadaway K. Alaine 3 http://orcid.org/0000-0002-1087-2182 Wang Yujie 2 http://orcid.org/0000-0001-8574-1972 Pozdeyev Nikita 11 http://orcid.org/0000-0002-2295-8637 Stæger Frederik F. 12 http://orcid.org/0000-0001-6782-1389 Yang Chaojie 13 Vanderwerff Brett 14 Patki Amit D. 15 Stalbow Lauren 4 Lin Meng 11 Rafaels Nicholas 11 http://orcid.org/0000-0002-7980-5420 Shortt Jonathan 11 http://orcid.org/0000-0001-6681-9754 Wiley Laura 11 http://orcid.org/0000-0001-7768-8868 Stanislawski Maggie 11 Pattee Jack 16 http://orcid.org/0000-0001-5143-2282 Davis Lea 17 Straub Peter S. 10 18 http://orcid.org/0000-0003-2866-3562 Shuey Megan M. 10 18 Cox Nancy J. 10 18 Lee Nanette R. 19 http://orcid.org/0000-0001-8356-5565 Jørgensen Marit E. 20 21 http://orcid.org/0000-0001-7153-8447 Bjerregaard Peter 21 Larsen Christina 21 http://orcid.org/0000-0001-8748-3831 Hansen Torben 22 http://orcid.org/0000-0001-7052-8554 Moltke Ida 12 Meigs James B. 23 Stram Daniel O. 24 http://orcid.org/0000-0001-6454-2384 Yin Xianyong 25 26 27 http://orcid.org/0000-0002-4331-7599 Zhou Xiang 26 27 http://orcid.org/0000-0001-6811-9364 Chang Kyong-Mi 28 29 http://orcid.org/0000-0002-6592-1172 Clarke Shoa L. 7 8 30 http://orcid.org/0000-0002-3614-9996 Guarischi-Sousa Rodrigo 7 8 Lankester Joanna 7 8 http://orcid.org/0000-0001-7274-9318 Tsao Philip S. 7 8 http://orcid.org/0000-0001-8539-5416 Buyske Steven 31 http://orcid.org/0000-0001-6380-1735 Graff Mariaelisa 2 http://orcid.org/0000-0002-7892-193X Raffield Laura M. 3 http://orcid.org/0000-0001-8324-2803 Sun Quan 32 Wilkens Lynne R. 33 Carlson Christopher S. 1 Easton Charles B. 34 35 http://orcid.org/0000-0003-2098-3844 Liu Simin 36 http://orcid.org/0000-0002-9426-7595 Manson JoAnn E. 23 Marchand Loïc L. 33 http://orcid.org/0000-0002-0097-9971 Haiman Christopher A. 24 http://orcid.org/0000-0001-6721-153X Mohlke Karen L. 3 http://orcid.org/0000-0001-5322-4188 Gordon-Larsen Penny 37 http://orcid.org/0000-0001-7306-031X Albrechtsen Anders 12 http://orcid.org/0000-0002-6442-7754 Boehnke Michael 14 http://orcid.org/0000-0003-3872-7793 Rich Stephen S. 13 http://orcid.org/0000-0002-5998-795X Manichaikul Ani 13 http://orcid.org/0000-0001-7191-1723 Rotter Jerome I. 38 Yousri Noha A. 39 40 Irvin Ryan M. 15 The biobank at the Colorado Center for Personalized Medicine (CCPM) http://orcid.org/0000-0001-8574-1972 Pozdeyev Nikita 11 Lin Meng 11 Pattee Jack 16 Anderson Heather D. 11 Aquilante Christina L. 11 Arbogast Kelsey 11 Arehart Christopher H. 11 Brooks Ian M. 11 Brunetti Tonya M. 11 Brutus-Lestin Judith 11 Burke Elizabeth E. 11 Casteel Emily M. 11 Cole Joanne B. 11 Coughlin Curtis R. II 11 Crooks Kristy 11 Crawford Jacob 11 Culver Erin 11 Edelmann Michelle N. 11 Fisher Matthew J. 11 Franklin Alan W. 11 Frye Teresa C. 11 George Hunter 11 Gignoux Chris 11 Gilliland Elizabeth K. 11 Greene Casey S. 11 Hawkes Brooke 11 Hearst Emily 11 Hendricks Audrey E. 11 Johnson Randi K. 11 Julian Colleen G. 11 Kao Dave 11 Konigsberg Iain 11 Ku Lisa 11 Kudron Elizabeth L. 11 Lacy Rashawnda 11 Lange Ethan M. 11 Lee Yee Ming 11 Lesny Joe A. 11 Lowery Jan T. 11 Vargas Luciana B. 11 Maldonado Betzaida L. 11 Marceau Darcy 11 Martin James L. 11 Gates Brianna L. 11 Mayer David 11 McDaniel Nicole L. 11 Monte Andrew 11 Moore Ethan 11 Nadrash Ann 11 Radwan Alaa 11 Rafaels Nick 11 Rasouli Neda 11 Shalowitz Elise L. 11 Sherif Hoda 11 Shortt Johnathan 11 Stewart Adrian M. 11 Sutton Kristen J. 11 Swartz Carolyn T. 11 Tanaka Anna 11 Taylor Matthew R. G. 11 Teague Candace 11 Todd Emily B. 11 Trinkley Katy E. 11 Wiley Laura K. 11 Raghavan Sridharan 11 42 VA Million Veteran Program (MVP) http://orcid.org/0000-0001-7274-9318 Tsao Philip S. 7 8 Muralidhar Sumitra 43 Moser Jennifer 44 Deen Jennifer E. 44 Gaziano J. Michael 45 Hauser Elizabeth 46 Kilbourne Amy 47 Matheny Michael 48 Oslin Dave 49 Voora Deepak 46 Brewer Jessica V. 45 Brophy Mary T. 45 Cho Kelly 45 Churby Lori 8 DuVall Scott L. 50 Pyarajan Saiju 45 Ringer Robert 51 Selva Luis E. 45 Shayan Shahpoor Alex 45 Stephens Brady 52 Whitbourne Stacey B. 45 Hung Adriana 53 Kranzler Henry 49 http://orcid.org/0000-0003-2349-0009 Assimes Themistocles L. 7 8 http://orcid.org/0000-0001-9728-6567 Gignoux Chris 11 http://orcid.org/0000-0002-8903-0366 North Kari E. 2 http://orcid.org/0000-0002-8532-5087 Loos Ruth J. F. 4 http://orcid.org/0000-0003-2349-0009 Assimes Themistocles L. 7 8 http://orcid.org/0000-0001-5666-9318 Peters Ulrike 1 41 http://orcid.org/0000-0002-7986-8560 Kooperberg Charles 1 Raghavan Sridharan 11 42 http://orcid.org/0000-0002-3583-8239 Highland Heather M. 2 http://orcid.org/0000-0002-6205-4632 Darst Burcu F. bdarst@fredhutch.org 1 1 https://ror.org/007ps6h72 grid.270240.3 0000 0001 2180 1622 Public Health Sciences, Fred Hutchinson Cancer Center, 2 https://ror.org/0130frc33 grid.10698.36 0000 0001 2248 3208 Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 3 https://ror.org/0130frc33 grid.10698.36 0000 0001 2248 3208 Department of Genetics, University of North Carolina at Chapel Hill, 4 https://ror.org/04a9tmd77 grid.59734.3c 0000 0001 0670 2351 The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, 5 https://ror.org/008s83205 grid.265892.2 0000 0001 0634 4187 Department of Epidemiology, University of Alabama at Birmingham, 6 https://ror.org/038321296 grid.249878.8 0000 0004 0572 7110 Data Science and Biotechnology, Gladstone Institutes, 7 https://ror.org/00f54p054 grid.168010.e 0000000419368956 Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, 8 https://ror.org/00nr17z89 grid.280747.e 0000 0004 0419 2556 VA Palo Alto Health Care System, 9 https://ror.org/05dq2gs74 grid.412807.8 0000 0004 1936 9916 Department of Biostatistics, Vanderbilt University Medical Center, 10 https://ror.org/02vm5rt34 grid.152326.1 0000 0001 2264 7217 Vanderbilt Genetic Institute, Vanderbilt University of Medical Center, 11 https://ror.org/03wmf1y16 grid.430503.1 0000 0001 0703 675X Colorado Center for Personalized Medicine, University of Colorado Anschutz Medical Campus, 12 https://ror.org/035b05819 grid.5254.6 0000 0001 0674 042X Department of Biology, Section for Computational and RNA Biology, University of Copenhagen, 13 https://ror.org/0153tk833 grid.27755.32 0000 0000 9136 933X Department of Genome Sciences, University of Virginia, 14 https://ror.org/00jmfr291 grid.214458.e 0000 0004 1936 7347 Department of Biostatistics and Center for Statistical Genetics, University of Michigan, 15 https://ror.org/008s83205 grid.265892.2 0000000106344187 Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, 16 https://ror.org/03wmf1y16 grid.430503.1 0000 0001 0703 675X Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, 17 https://ror.org/04a9tmd77 grid.59734.3c 0000 0001 0670 2351 Department of Medicine, Division of Data-Driven and Digital Medicine, Icahn School of Medicine at Mount Sinai, 18 https://ror.org/02vm5rt34 grid.152326.1 0000 0001 2264 7217 Department of Medicine, Division of Genetic Medicine, Vanderbilt University of Medical Center, 19 https://ror.org/041jw5813 grid.267101.3 0000 0001 0672 9351 USC-Office of Population Studies Foundation, Inc., University of San Carlos, 20 21 https://ror.org/03yrrjy16 grid.10825.3e 0000 0001 0728 0170 Centre for Public Health in Greenland, National Institute of Public Health, University of Southern Denmark, 22 https://ror.org/035b05819 grid.5254.6 0000 0001 0674 042X Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, 23 https://ror.org/03vek6s52 grid.38142.3c 000000041936754X Department of Medicine, Mass General Brigham Healthcare System, Harvard Medical School, 24 https://ror.org/03taz7m60 grid.42505.36 0000 0001 2156 6853 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 25 https://ror.org/059gcgy73 grid.89957.3a 0000 0000 9255 8984 Department of Epidemiology, School of Public Health, Nanjing Medical University, 26 https://ror.org/00jmfr291 grid.214458.e 0000 0004 1936 7347 Department of Biostatistics, University of Michigan, 27 https://ror.org/00jmfr291 grid.214458.e 0000 0004 1936 7347 Center for Statistical Genetics, University of Michigan, 28 https://ror.org/03j05zz84 grid.410355.6 0000 0004 0420 350X Corporal Michael J. Crescenz VA Medical Center, 29 https://ror.org/00b30xv10 grid.25879.31 0000 0004 1936 8972 Department of Medicine, Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, 30 https://ror.org/00f54p054 grid.168010.e 0000000419368956 Department of Medicine, Stanford Prevention Research Center, Stanford University School of Medicine, 31 https://ror.org/05vt9qd57 grid.430387.b 0000 0004 1936 8796 Department of Genetics, Rutgers University, 32 https://ror.org/0130frc33 grid.10698.36 0000 0001 2248 3208 Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 33 https://ror.org/00kt3nk56 Epidemiology Program, University of Hawaii Cancer Center, 34 https://ror.org/05gq02987 grid.40263.33 0000 0004 1936 9094 Department of Epidemiology, School of Public Health, Brown University, 35 https://ror.org/05gq02987 grid.40263.33 0000 0004 1936 9094 Department of Family Medicine, Warren Alpert Medical School, Brown University, 36 https://ror.org/05gq02987 grid.40263.33 0000 0004 1936 9094 Department of Epidemiology, School of Public Health, Brown University, 37 https://ror.org/0130frc33 grid.10698.36 0000 0001 2248 3208 Department of Nutrition, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, 38 https://ror.org/025j2nd68 grid.279946.7 0000 0004 0521 0744 Department of Pediatrics, The Institute for Translational Genomics and Population Sciences, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, 39 https://ror.org/03eyq4y97 grid.452146.0 0000 0004 1789 3191 College of Health and Life Sciences, Hamad Bin Khalifa University, 40 https://ror.org/00mzz1w90 grid.7155.6 0000 0001 2260 6941 Computer and Systems Engineering, Alexandria University, 41 https://ror.org/00cvxb145 grid.34477.33 0000000122986657 Department of Epidemiology, School of Public Health, University of Washington, 42 https://ror.org/04cqn7d42 grid.499234.1 0000 0004 0433 9255 Department of Medicine, Division of General Internal Medicine, University of Colorado School of Medicine, 43 https://ror.org/05rsv9s98 grid.418356.d 0000 0004 0478 7015 US Department of Veterans Affair, 44 https://ror.org/05rsv9s98 grid.418356.d 0000 0004 0478 7015 US Department of Veterans Affairs, 45 https://ror.org/04v00sg98 grid.410370.1 0000 0004 4657 1992 VA Boston Healthcare System, 46 https://ror.org/034adnw64 grid.410332.7 0000 0004 0419 9846 Durham VA Medical Center, 47 https://ror.org/018txrr13 grid.413800.e 0000 0004 0419 7525 VA Ann Arbor Healthcare System, 48 https://ror.org/01c9rqr26 grid.452900.a 0000 0004 0420 4633 VA Tennessee Valley Healthcare System, 49 https://ror.org/03j05zz84 grid.410355.6 0000 0004 0420 350X Philadelphia VA Medical Center, 50 https://ror.org/007fyq698 grid.280807.5 0000 0000 9555 3716 VA Salt Lake City Health Care System, 51 https://ror.org/04n9z8z70 grid.413580.b 0000 0000 9831 362X New Mexico VA Health Care System, 52 https://ror.org/00m8atr56 grid.477016.3 0000 0004 0420 1440 Canandaigua VA Medical Center, 53 https://ror.org/01c9rqr26 grid.452900.a 0000 0004 0420 4633 VA Tennessee Valley Healthcare System, 1 10 2025 2025 16 478256 8632 8 4 2025 22 8 2025 01 10 2025 03 10 2025 03 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by/4.0/ Open Access http://creativecommons.org/licenses/by/4.0/ Polygenic risk scores hold prognostic value for identifying individuals at higher risk of type 2 diabetes. However, further characterization is needed to understand the generalizability of type 2 diabetes polygenic risk scores in diverse populations across various contexts. We systematically characterize a multi-ancestry type 2 diabetes polygenic risk score among 244,637 cases and 637,891 controls across diverse populations from the Population Architecture Genomics and Epidemiology Study and 13 additional biobanks and cohorts. Polygenic risk score performance is context dependent, with better performance in those who are younger, male, without hypertension, and not obese or overweight. Additionally, the polygenic risk score is associated with various diabetes-related cardiometabolic traits and type 2 diabetes complications, suggesting its utility for stratifying risk of complications and identifying shared genetic architecture between type 2 diabetes and other diseases. These findings highlight the need to account for context when evaluating polygenic risk score as a tool for type 2 diabetes risk prognostication and the potentially generalizable associations of type 2 diabetes polygenic risk score with diabetes-related traits, despite differential performance in type 2 diabetes prediction across diverse populations. Our study provides a comprehensive resource to characterize a type 2 diabetes polygenic risk score. Polygenic risk scores can help identify individuals at higher risk of type 2 diabetes. Here, the authors characterise a multi-ancestry score across nearly 900,000 people, showing that its predictive value depends on demographic and clinical context and extends to related traits and complications. Subject terms Type 2 diabetes Personalized medicine Population genetics Disease genetics https://doi.org/10.13039/100000002 U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01HL143885 R01HD30880 R01HL151152 R01DK139598 R01HL142302 R01HL143885 R01HL163262 R01DK122503 R01HL151152 R01HL156991 R01DK123019 UM1DK078616 R00CA246063 R03CA287235 U01CA261339 R01HL174378 U54HG013243 Gordon-Larsen Penny Gignoux Chris North Kari E. Loos Ruth J. F. Kooperberg Charles Darst Burcu F. https://doi.org/10.13039/100008982 Qatar National Research Fund (QNRF) PPM2-0226–170020 NPRP11S-0114–180299 Yousri Noha A. https://doi.org/10.13039/501100009708 Novo Nordisk Fonden (Novo Nordisk Foundation) NNF20OC0059313 NNF18CC0034900 Loos Ruth J. F. https://doi.org/10.13039/100000054 U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P50CA097186 P30CA015704 Darst Burcu F. This work was also supported an award from the Andy Hill Cancer Research Endowment Distinguished Researchers Program (B.F.D), and a Fred Hutchinson Cancer Center Translational Data Science New Collaboration Award(B.F.D.). pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer Nature Limited 2025 Introduction The rise in type 2 diabetes (T2D) prevalence is a major public health challenge that shows no signs of abating. Without sufficient efforts to combat this pandemic, it has been estimated that 11.3% of the global population will have diabetes by 2030 1 2 An emerging and promising approach to quantify T2D risk is the use of polygenic risk scores (PRS), which model the aggregate effect of genetic variants found across the genome on a disease or trait of interest. Such scores, combined with non-genetic predictors, potentially hold utility for identifying individuals at high risk prior to disease onset and could guide positive health behavior changes, screening practices, or therapeutic interventions 3 5 6 8 Given the large number of risk factors for T2D, there is a clear need to further characterize PRS. Although previous studies have reported that interactions between individual genetic variants and certain lifestyle factors influence T2D risk in European ancestry populations 8 11 7 The Population Architecture using Genomics and Epidemiology (PAGE) Study, which consists of multiple large and diverse population-based studies, is uniquely situated to address these questions. In PAGE, we previously found that a multi-ancestry T2D PRS outperformed population-specific T2D PRS and explained up to 15.3% of familial relative risk of T2D across populations 8 Results Participants An overview of the study design is provided in Fig. 1 1 1 2 Supplemental Information Fig. 1 Workflow of T2D PRS construction and evaluation. Four T2D PRS were constructed and evaluated in the Population Architecture using Genomics and Epidemiology (PAGE) study to identify the best-performing score for downstream analyses. The best-performing PRS across populations was used for stratified analyses across demographic, medical, and lifestyle and behavioral characteristics, and association analyses with diabetes-related traits in PAGE. Stratified and association analyses were replicated in 11 independent cohorts. Phenome-wide association studies (PheWAS) were conducted across five independent biobanks to assess the broader clinical impact of the T2D PRS. Table 1 Sample sizes of populations included by T2D status Population T2D cases T2D controls Prediabetes Total African, African American, or Black (AFR) 52,159 106,306 2333 160,798 American Indian, Alaskan Native, or Native American (AI) 177 374 91 642 Asian American, East of Southeast Asian, or South Asian/Indian (ASN) 6999 17,660 3134 27,793 White or European American (EUR) 148,230 441,879 18,126 608,235 Greenlandic 586 426 2824 3836 Hispanic/Latino American (HIS) 32,440 65,613 8955 107,008 Middle Eastern, North African, or Qatari (MENAQ) 2352 3078 53 5483 Native Hawaiian or Other Pacific Islander (NH) 1694 2555 141 4390 Total 244,637 637,891 35,657 918,185 Evaluation of T2D PRS performance Given our unique populations and how rapidly PRS are superseded, our first goal was to identify a T2D PRS that had optimal predictive ability across our populations to be carried forward in subsequent PRS evaluations. In PAGE, we assessed four distinct multi-ancestry PRS (Fig. 1 3 12 13 15 PRS Method 1 16 17 18 19 PRS Method 2 6 7 PRS Method 3 PRS Method 4 7 8 Each of the four T2D PRS methods exhibited good predictive performance in PAGE (Supplementary Data 4 2A 4 Fig. 2 Performance of T2D PRS across self-identified populations. A 1 B A B 1 In PAGE, the PRS was highly predictive of T2D risk across populations but with variable performance (Supplementary Fig. 1 2B 5 2 2 As a secondary analysis, we evaluated the association between the T2D PRS and age at T2D diagnosis (Fig. 3 6 P −78 6 P −9 P −3 P −4 P −7 Fig. 3 Distribution of age at T2D diagnosis by PRS decile and population in All of Us. Data are presented as mean age at diagnosis with standard error. Sample sizes are provided in Supplementary Data 6 Context-dependent effects of T2D PRS We investigated whether the T2D PRS demonstrated context-dependent effects on T2D risk by conducting association analyses stratified by 18 demographic, medical, lifestyle, and behavioral characteristics, and evaluating effect heterogeneity using Cochran’s Q 7 4 8 12 Fig. 4 Effect of the T2D PRS on T2D risk stratified by demographic, medical, and lifestyle and behavioral factors meta-analyzed across PAGE and the additional biobanks and cohorts. Data are presented as odds ratio (OR) with 95% confidence interval (CI). P Q P A B C D A D 9 Specifically, in meta-analyses across all populations, the T2D PRS was associated with significantly higher risk of T2D in younger individuals (age ≤50 years: OR = 1.91 (95% CI: 1.88, 1.94); age 50–60 years: OR = 1.85 (95% CI: 1.83, 1.88); age 60–70 years: OR = 1.81 (95% CI: 1.79, 1.83); age >70 years: OR = 1.68 (95% CI: 1.66, 1.71); P het −28 P het −38 P het −03 P het −56 P het 4 9 3 10 11 8 10 PRS had a stronger effect in never smokers and former smokers compared to current smokers ( P het −18 P het −3 Association between T2D PRS and diabetes-related traits Next, to investigate the clinical implications of genetic risk of T2D, we examined associations between the T2D PRS and 20 diabetes-related traits across five primary phenotype categories: glycemic traits, cardiometabolic traits, vascular diseases, kidney diseases and functions, and inflammatory biomarkers, stratified by T2D status in AFR, ASN, EUR, HIS, and all populations combined (see the “Methods” section and Supplementary Data 13 P −3 5 14 15 16 R 2 15 Fig. 5 Effect of T2D PRS on diabetes-related traits meta-analyzed across PAGE and the additional biobanks and cohorts. The X P P P −3 A B 13 14 4 We first examined the associations between T2D PRS and glycemic traits among T2D controls, as glycemic measurements in T2D cases are influenced by diabetes medications. Each SD increase in the T2D PRS was significantly associated with 0.034 (95% CI: 0.031, 0.037) higher units of HbA1c levels and 0.030 mmol/L (95% CI: 0.026, 0.035) higher fasting glucose levels in individuals without T2D (Fig. 5A P −4 Regarding cardiometabolic traits, each SD increase in PRS was associated with a 1.04-fold increased risk (95% CI: 1.03, 1.05) of hypertension in T2D controls across all populations, a 1.04-fold (95% CI: 1.02, 1.06) and 1.03-fold (95% CI: 1.02, 1.04) increased risk in EUR cases and controls, and a 1.10-fold (95% CI: 1.07, 1.13) increased risk in HIS controls (Fig. 5B P −25 P −6 P −68 P −5 P −5 For kidney diseases, the PRS was associated with a 1.08-fold increased risk (95% CI: 1.03, 1.13) of end stage renal disease (ESRD) in T2D cases across all populations (Supplementary Fig. 4B T2D PRS PheWAS To further investigate the prognostic value of the T2D PRS and clinical phenotypes, we conducted a comprehensive PheWAS meta-analysis of the T2D PRS on 1,815 unique phenotypes representing 17 disease categories tested across five biobanks. We identified significant associations between the T2D PRS and 732 traits (40.3% of all phecodes tested) across all populations combined at Bonferroni adjusted significance ( P −5 6 5 17 7 r r r r Fig. 6 T2D PRS PheWAS results meta-analyzed across all five biobanks and populations. The X Y 10 p p P −5 p P Fig. 7 Comparison of significant associations and effect sizes of T2D PRS PheWAS results by population. A B The 732 significant associations encompassed phenotypes related to the circulatory system ( n n n n n n P −324 2 6 P −173 P −173 P −18 P −324 P −128 Table 2 Significant meta-analyzed phenome-wide associations (meta-PheWAS) between T2D PRS and clinical diseases across all populations Phecode Phenotype Disease category OR P 250.2 Type 2 diabetes Endocrine/Metabolic 2.38 <5E−324 250.7 Diabetic retinopathy Endocrine/Metabolic 2.52 <5E−324 250.3 Insulin pump user Endocrine/Metabolic 2.19 <5E−324 250.6 Polyneuropathy in diabetes Endocrine/Metabolic 2.23 <5E−324 250 Diabetes mellitus Endocrine/Metabolic 1.80 <5E−324 250.1 Type 1 diabetes Endocrine/Metabolic 2.05 <5E−324 272.1 Hyperlipidemia Endocrine/Metabolic 1.27 <5E−324 249 Secondary diabetes mellitus Endocrine/Metabolic 2.05 <5E−324 250.4 Abnormal glucose Endocrine/Metabolic 1.36 <5E−324 276.13 Hyperpotassemia Endocrine/Metabolic 1.36 <5E−324 401.1 Essential hypertension Circulatory system 1.34 <5E−324 536.3 Gastroparesis Digestive 1.46 6.66E−142 366.2 Senile cataract Sense organs 1.27 <5E−324 585.3 Chronic renal failure Genitourinary 1.34 <5E−324 710.11 Acute osteomyelitis Musculoskeletal 1.65 1.55E−225 509.1 Respiratory failure Respiratory 1.19 1.44E−149 871.3 Open wound of foot except toe(s) alone Injuries & poisonings 1.49 2.97E−168 351 Other peripheral nerve disorders Neurological 1.16 5.25E−181 707.2 Chronic ulcer of leg or foot Dermatologic 1.54 <5E−324 318 Tobacco use disorder Mental disorders 1.09 1.07E−98 285.21 Anemia in chronic kidney disease Hematopoietic 1.50 <5E−324 782.3 Edema Symptoms 1.15 2.91E−149 208 Benign neoplasm of colon Neoplasms 1.08 7.55E−70 110.1 Dermatophytosis Infectious diseases 1.10 1.38E−38 747.1 Cardiac congenital anomalies Congenital anomalies 1.06 1.45E−07 649.1 Diabetes or abnormal glucose tolerance complicating pregnancy Pregnancy Complications 1.46 6.32E−84 If a Phecode with the same one-decimal value (e.g., 250.2) is listed, more specific phecodes (e.g., 250.24) are excluded; otherwise, the specific phecode is shown. The top ten associations in the endocrine/metabolic disease category are shown, while the top one association is shown for other phenotype categories. All associations shown passed Bonferroni-adjusted p P −5 17 The single top phenotype associated with the T2D PRS from other phenotype groups, all of which were positively associated, were essential hypertension, CKD, senile cataract, chronic ulcer of leg or foot, anemia in chronic kidney disease, acute osteomyelitis, other peripheral nerve disorders, open wound of foot, respiratory failure, edema, gastroparesis, tobacco use disorder, diabetes or abnormal glucose tolerance complicating pregnancy disorder, benign neoplasm of colon, dermatophytosis, and cardiac congenital anomalies. Discussion In this large-scale T2D investigation of more than 240,000 T2D cases and 630,000 controls from PAGE and 13 independent biobanks and studies, we performed the first comprehensive and systematic cross-population characterization of a multi-ancestry genome-wide T2D PRS. This was achieved using a harmonized framework to evaluate context-dependent T2D PRS effects across different demographic and clinical characteristics, T2D PRS associations with diabetes-related traits, and a PheWAS of the T2D PRS. Our findings demonstrate that the PRS holds predictive value for T2D risk across diverse populations and was associated with younger age at T2D diagnosis. The T2D PRS demonstrated context-dependent associations with T2D risk, with PRS performance varying by certain demographic and clinical characteristics, such as age, sex, hypertension, and obesity status. Additionally, we found that the genetic risk of T2D, as measured by the T2D PRS, was associated with other glycemic and cardiometabolic traits in controls, suggesting that PRS could provide insights into T2D etiology and serve as a valuable tool for predicting dysglycemia and metabolic risk, thereby facilitating early interventions and improving clinical risk assessment. Notably, associations between the T2D PRS and diabetes-related traits and complications were often consistent across populations, despite variable between-population PRS performance in estimating T2D risk, suggesting that the PRS may have clinical and prognostic utility beyond T2D risk prediction. Our PheWAS found associations between the T2D PRS and 40.3% of tested phenotypes, including phenotypes across all disease categories tested, underscoring the pleiotropic effects of T2D genetic risk and suggesting a broad biological impact of T2D-associated variants across organ systems. By providing a comprehensive resource that characterizes T2D PRS across diverse populations, our findings move beyond European-centric discovery and evaluate whether PRS utility—both predictive and prognostic—depends on individual- and population-level contexts. Future applications of T2D PRS in precision medicine should consider not only ancestry-specific calibration but also how environmental, metabolic, and clinical factors modulate the phenotypic expression of genetic risk. We found that a multi-ancestry PRS was strongly associated with increased risk of T2D in all populations examined, yielding an overall OR of 1.75 (95% CI: 1.71, 1.78) and AUC of 0.641 (95% CI: 0.636, 0.645). The PRS performance across studies was generally comparable, with small variations likely due to study-specific differences, such as study design and phenotype definition. However, we observed larger variations in the performance of T2D PRS across populations, with the highest predictive performance in the AI population (although sample sizes were small), followed by EUR, ASN, NH, HIS, and AFR populations. These findings are consistent with what has been previously reported 8 16 20 Despite the lower predictive ability of the T2D PRS in AFR and HIS populations, we observed the strongest evidence of the PRS being associated with a younger age at T2D diagnosis in these two populations, demonstrating potential clinical utility. AFR and HIS populations tended to develop diabetes earlier than ASN and EUR populations; while these differences could be partially attributed to the younger age at enrollment in these populations (mean age at enrollment: AFR = 54.7 [SD: 10.2], HIS = 53.3 [SD: 11.4], ASN = 54.5 [SD: 12.5], EUR = 60.5 [SD: 12.5]), similar differences in age at T2D diagnosis have been previously reported 21 Our results show that the prediction accuracy of PRS is context-dependent and can vary even within populations. We consistently observed that the T2D PRS was particularly informative for predicting T2D susceptibility in younger individuals, those without hypertension, males, and individuals who were not obese or overweight, across and within populations. The stronger predictive ability in younger individuals is consistent with published literature, such as the findings from the Framingham Offspring Study 22 9 23 25 26 27 28 29 8 9 30 Prior research on the performance of T2D PRS stratified by sex is limited 9 31 32 35 36 38 IRS1 KCNQ1 39 42 41 42 41 Collectively, these interactions between the T2D PRS and non-genetic factors demonstrate the complex nature of T2D risk and the importance of interpreting the genetic risk of T2D in the context of non-genetic risk factors. Our findings suggest that across diverse populations, genetic effects can vary across contexts and that PRS may exhibit context-specific performance. This indicates that risk prediction models will need to include not only PRS but demographic, medical, lifestyle and behavioral characteristics, and their interactions 36 We found that the T2D PRS was associated with various diabetes-related traits and disease conditions across diverse populations, providing compelling evidence that the T2D PRS could provide insights into T2D prognosis. We observed consistent associations between T2D PRS and glycemic parameters in T2D controls, with significant positive associations for fasting glucose and HbA1c, as well as associations with cardiometabolic traits, including hypertension, SBP, triglycerides, and HDL cholesterol, in both T2D cases and controls. These findings suggest that T2D PRS may serve as a valuable tool for early identification of individuals at risk for developing dysglycemia and cardiometabolic complications, even among those who are currently asymptomatic or undiagnosed. Our findings also have important implications for T2D etiology and pathophysiology. For instance, the positive association between T2D PRS and HOMA-IR in EUR controls provides genetic evidence that complements previous epidemiological studies on the critical role of insulin resistance in T2D development 43 45 Findings from our PheWAS across 1815 diseases and conditions and five biobanks further demonstrated significant associations between T2D PRS and various clinical comorbidities, including those related to the circulatory system, endocrine and metabolic disorders, lipid abnormalities, and kidney diseases. Notably, these associations were consistently observed across populations, with fairly correlated effect estimates. Despite the variability in PRS performance for T2D risk estimation across populations, our findings suggest that genetic mechanisms underlying T2D and diabetes-related traits are shared across populations. As such, the PRS may serve as a valuable tool for stratifying the risk of complications in individuals diagnosed with T2D across diverse populations. The positive association between T2D PRS and micro- and macrovascular complications, such as retinopathy, neuropathy, CKD, cardiovascular diseases, and peripheral artery disease, has also been reported by prior studies 7 46 47 48 The results of our study should be interpreted considering several limitations. We used self-identified race and ethnicity (SIRE) population descriptors to determine whether the T2D PRS had discrepancies in performance in the contexts of SIRE. Although other sociodemographic and environmental factors may be more informative than SIRE, because our investigation included a large number of studies, many of which include legacy data collected up to 37 years ago, this study was limited by the variables available across all included studies. Further, SIRE information was collected differently between studies (Supplementary Data 2 In conclusion, our large-scale, systematic and cross-population investigation highlights the predictive value of the T2D PRS across diverse populations, emphasizing its potential as a promising tool for identifying individuals at elevated risk of developing T2D and its associated comorbidities and complications, shedding light on potential avenues for risk prediction and personalized management strategies. Our findings also demonstrate that the T2D PRS has context-dependent effects, indicating the need to account for these characteristics to interpret PRS and improve PRS prediction accuracy. Further research is warranted to evaluate and optimize the clinical utility of T2D PRS across diverse populations. Methods Participants The PAGE Study was developed to conduct genetic epidemiological research in ancestrally diverse populations within the United States 49 50 51 52 53 54 55 49 Supplemental Information 1 Analyses were also conducted in 13 additional biobanks and cohorts that were not included in the discovery GWAS summary statistics of the best-performing T2D PRS. Studies included All of Us (AoU) 56 57 58 59 60 61 62 64 65 66 67 69 70 71 1 Our research complies with all relevant ethical regulations regarding the use of human study participants and was conducted in accordance to the criteria set by the Declaration of Helsinki. All participants provided informed consent, and each study was approved by the appropriate Institutional Review Board at their respective institutions. Additional information about each participating study can be found in the Supplementary Information Use of population descriptors Self-identified race and ethnicity (SIRE) population descriptors were used across studies, with the goal of studying how PRS performance may vary across the contexts of SIRE. Although other sociodemographic and environmental factors are expected to be more informative than SIRE, this investigation is limited by the variables that are currently available across all included studies. It is important to note that SIRE does not serve as a proxy for genetic ancestry, holds no biological basis, and does not imply a biological explanation for health disparities 72 We standardized population descriptors across all studies in the analysis by using consistent acronyms. Specifically, AFR refers to African, African American, or Black participants; AI refers to American Indian, Alaskan Native, or Native American; ASN includes Asian American, East or Southeast Asian (e.g., from China, Japan, Korea, Indonesia, the Philippines), as well as South Asian/Indian (e.g., from India, Pakistan); EUR refers to non-Hispanic White American or European individuals; Greenlandic refers to individuals of Greenlandic or mixed Greenlandic-Danish heritage; HIS represents Hispanic/Latino American participants; MENAQ encompasses Qatari and Arab American individuals; and NH refers to Native Hawaiian or Other Pacific Islander. The Greenlandic population was considered separate from others, as this population represents substantial Inuit ancestry 63 2 T2D and prediabetes definition T2D and prediabetes definitions were created based on the American Diabetes Association’s 2021 Standards of Medical Care in Diabetes 73 Supplemental Information Genotyping, imputation, and quality control This study included 36,724 PAGE participants who met the T2D and prediabetes definitions and underwent genotyping using the Multi-Ethnic Genotyping Array (MEGA) panel, specifically designed to capture genetic heterogeneity across diverse populations, with the remaining 46,220 PAGE participants genotyped using a variety of other arrays (Supplementary Data 1 74 https://imputation.biodatacatalyst.nhlbi.nih.gov/#! 69 75 76 N N 77 79 Construction of T2D PRS Participants included in this investigation were not part of the discovery GWAS used to develop the T2D PRS. PRS for each participant were constructed as the weighted sum of effect alleles, weighted by variant-specific log ORs using “--score” option with “cols = +scoresums” modifier in PLINK 2.0 80 The R package “rtracklayer” 81 82 PRS-CSx estimates population-specific and multi-ancestry PRS by jointly modeling discovery GWAS summary statistics and pre-calculated linkage disequilibrium (LD) reference panels based on the 1000 Genomes Project (1KG) Phase 3 participants from AFR, Admixed American (AMR), EAS, EUR, and SAS population samples 12 ϕ PRS Method 1 PRS Method 2 PRS Method 3 PRS Method 3 The following logistic regression model of the standardized population-specific PRS was fit in the validation dataset for each population: 1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${\\mathrm{logit}}(p) \\sim \\, \t {\\beta }_{0}+{\\beta }_{{\\mathrm{HIS}}}\\times {{\\mathrm{PRS}}}_{{\\mathrm{HIS}}}+{{\\beta }_{{\\mathrm{AFR}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{AFR}}}+{{\\beta }_{{\\mathrm{EAS}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{EAS}}} \\\\ \t+{{\\beta }_{{\\mathrm{EUR}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{EUR}}}+{{\\beta }_{{\\mathrm{SAS}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{SAS}}},$$\\end{document} logit ( p ) ~ β 0 + β HIS × PRS HIS + β AFR × PRS AFR + β EAS × PRS EAS + β EUR × PRS EUR + β SAS × PRS SAS , \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${{\\rm{l}}}{{\\rm{o}}}{{\\rm{g}}}{{\\rm{i}}}{{\\rm{t}}}(p)$$\\end{document} l o g i t ( p ) β 0 β \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\left({w}_{k}\\right)$$\\end{document} w k 2 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${\\mathrm{Final}}\\,{\\mathrm{linear}}\\,{\\mathrm{combination}}\\,{\\mathrm{PRS}}=\t {w}_{{\\mathrm{HIS}}}\\times {{\\mathrm{PRS}}}_{{\\mathrm{HIS}}}+{{w}_{{\\mathrm{AFR}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{AFR}}} \\\\ \t+{{w}_{{\\mathrm{EAS}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{EAS}}}+{{w}_{{\\mathrm{EUR}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{EUR}}} \\\\ \t+{{w}_{{\\mathrm{SAS}}}\\times {\\mathrm{PRS}}}_{{\\mathrm{SAS}}}$$\\end{document} Final linear combination PRS = w HIS × PRS HIS + w AFR × PRS AFR + w EAS × PRS EAS + w EUR × PRS EUR + w SAS × PRS SAS We assessed the predictive accuracy of the four T2D PRS within each population in PAGE using AUCs. AUC values were calculated using the R package “pROC” 83 Association between T2D PRS and age at T2D diagnosis We evaluated the association between the T2D PRS and age at T2D diagnosis in a case-only analysis in All of Us. This analysis was limited to All of Us due to its large sample size, inclusion of multiple populations, and the ability to estimate age at diagnosis. Age at diagnosis was determined by the earliest occurrence start date of T2D mellitus (SNOMED concept ID: 201826), T2D mellitus without complication (SNOMED concept ID: 4193704), or disorder due to T2D mellitus (SNOMED concept ID: 443732). We tested the association between each PRS category (predictor) and age at diagnosis (outcome) in linear regression models, using the 0–10% PRS decile as the reference. Analyses were performed separately in each population and across all populations. Stratification analyses We investigated the context-dependent effects of the best-performing T2D PRS in analyses stratified by demographic characteristics and medical history (age group, self-reported sex at birth, family history (FH) of T2D, and blood pressure categories), behavioral and lifestyle factors (obesity status, current drinking status, smoking status, and physical activity level), medication use (statin, NSAID, fibrates, lipid-lowering medication, and anti-hypertensive medication), and lipid traits (HDL, LDL, triglycerides, total cholesterol (TC), and non-HDL quartiles) (definitions provided in Supplementary Data 7 Q P Q \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${P}_{{{\\rm{het}}}}$$\\end{document} P het P T2D PRS associations with diabetes-related traits We next examined the ability of the best performing T2D PRS to predict 20 traits and complications, including glycemic traits (fasting glucose, fasting insulin, HOMA-IR, and HbA1c), cardiometabolic traits (HDL, LDL, triglycerides, TC, non-HDL, systolic and diastolic blood pressure, and hypertension), vascular diseases (heart attack and stroke), kidney diseases and functions (end stage renal disease, chronic kidney disease, urine albumin-creatine ratio, and eGFR), and inflammatory biomarkers (CRP and IL6) (Supplementary Data 13 R 2 P −3 PheWAS To further understand the clinical implications of T2D PRS on the risk of other diseases and conditions, we conducted phenome-wide association studies (PheWASs) in five independent biobanks: BioMe, BioVU, CCPM, MVP, and MGI. Utilizing the PheWAS R package 84 P P −5 P −5 P −5 P −5 P −5 P −324 Meta-analysis Results from PAGE and the 13 additional biobanks and cohorts were first meta-analyzed using inverse variance weighted fixed-effect models within populations to obtain population-specific results for AFR, ASN, EUR, and HIS populations. The results from these four populations, along with the results from all other populations (AI, Greenlandic, MENAQ, and NH), were included in the larger meta-analysis conducted among all populations combined. PheWAS results were similarly meta-analyzed across the five biobanks for each of the four populations and across all populations combined. The degree of heterogeneity was evaluated using the τ 2 I 2 All statistical analyses were performed using R (version 4.1.2). Reporting summary Further information on research design is available in the Nature Portfolio Reporting Summary Supplementary information  Supplementary Information Description of Additional Supplementary Files Supplementary Data 1-17 Reporting Summary Transparent Peer Review file Publisher’s note Lists of authors and their affiliations appear at the end of the paper. Lists of members and their affiliations appears in the Supplementary Information. Supplementary information The online version contains supplementary material available at 10.1038/s41467-025-63546-4. Acknowledgements This work was supported by the National Institutes of Health (R01HL151152 to C.K., C.G., and K.E.N., R00CA246063, R03CA287235, U01CA261339, R01HL174378, P50CA097186, P30CA015704, and U54HG013243 to B.F.D., R01HL143885 and R01DK139598 to P.G.-L. and K.E.N., R01HL163262, R01DK122503, and R01HL142302 to K.E.N., UM1DK078616 to C.K., R01HD30880 and R01AG065357 to P.G.-L., R01DK124097, R01HL156991, and R01DK123019 to R.J.F.L.), an award from the Andy Hill Cancer Research Endowment Distinguished Researchers Program (B.F.D.), and a Fred Hutchinson Cancer Center Translational Data Science New Collaboration Award (B.F.D). R.J.F.L. is supported by grants from the Novo Nordisk Foundation (NNF20OC0059313, NNF23SA0084103, and NNF18CC0034900). Work done by N.A.Y. was made possible by PPM2 grant #PPM2-0226–170020 from the Qatar National Research Fund (QNRF) and Qatar Genome Program (QGP) (members of Qatar Foundation) and by NPRP-S11 grant #NPRP11S-0114–180299 from the Qatar National Research Fund. The full acknowledgments and funding for the individual studies are listed in the Supplementary Information Author contributions B.F.D., H.M.H., S.R., and R.A.J.S. contributed to study conception and design. B.G. and B.F.D. wrote the manuscript. C.K., C.G., and K.E.N. contributed to funding acquisition. Central data analysis group: B.G. (PAGE), D.K. (CCHC), Z.W. (BioMe), J.H. (AoU), R.T. (BioVU), K.A.B. (CLHNS), Y.W. (CHNS), N.P. and M.L. (CCPM), F.F.S. (Greenlandic), C.Y. (MESA), B.V. (MGI), K.R.I. and A.T.H. (MVP), N.A.Y. (Qatar), and A.D.P. (REGARDS) contributed to data analysis and interpretation. Study level principal investigators: K.L.M. (CLHNS), P.G.-L. (CHNS), A.A. (Greenlandic), M.B. (MGI), S.S.R. (MESA), A.M. and J.I.R. (MESA), R.M.I. (REGARDS), C.G. (CCPM), K.E.N. (CCHC), R.J.F.L. (BioMe), T.L.A. (MVP), C.A.H., L.L.M., and L.R.W. (MEC), and C.K. (WHI) contributed data and provided resource and administrative support. PAGE, AoU, BioMe, BioVU, CCHC, CCPM, CLHNS, CHNS, Greenlandic, MESA, MGI, MVP, Qatar, and REGARDS provided the data and administrative support. Additional contributions: Y.C., L.S., N.R., J. Shortt, L.W., M. Stanislawski, J. Pattee, L.D., P.S.S., M.M.S., N.J.C., N.R.L., M.E.J., P.B., C.L., T.H., I.M., J.B.M., D.O.S., X.Y., X.Z., K.-M.C., S.L.C., R.G.-S., J.L., P.S.T., S.B., M.G., L.M.R., Q.S., C.S.C., C.B.E., S.L., J.E.M., and U.P. contributed to design, data collection, management, coordination, interpretation, and/or analysis of contributing studies. B.F.D. and H.M.H. supervised the work. B.F.D. takes responsibility for the integrity and accuracy of the manuscript. All authors critically reviewed and approved the final version of the manuscript. Peer review Peer review information Nature Communications Data availability The Ge et al. T2D PRS [10.1186/s13073-022-01074-2] and the T2D PRS of 582 variants [10.1038/s41588-020-0637-y; 10.1016/j.xhgg.2021.100029] are available on the PGS Catalog under accession numbers: PGS002308 PGS000804 PGP000742 https://diagram-consortium.org/downloads.html phs001672.v12.p1 https://github.com/getian107/PRScsx Code availability All data and statistical analysis tools used in the present study are open source, details of which are available in the “Methods” section and Nature Portfolio Reporting Summary. No customized code was used to process or analyze data. PRS were calculated using PLINK 2.0 [ https://www.cog-genomics.org/plink/2.0/ https://github.com/getian107/PRScsx Competing interests R.J.F.L. has acted as a member of advisory boards and as a speaker for Ely Lilly and the Novo Nordisk Foundation, for which she has received fees. L.M.R. is a consultant for the NHLBI TOPMed Administrative Coordinating Center (through Westat). U.P. was a consultant with AbbVie, and her husband holds individual stocks for the following companies: BioNTech SE—ADR, Amazon, CureVac BV, Google/Alphabet Inc Class C, NVIDIA Corp, Microsoft Corp. The remaining authors declare no competing interests. References 1. International Diabetes Federation. IDF Atlas 2021 2. Bommer C Global economic burden of diabetes in adults: projections from 2015 to 2030 Diabetes Care 2018 41 963 970 10.2337/dc17-1962 29475843 Bommer, C. et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Diabetes Care 41 29475843 10.2337/dc17-1962 3. Khera AV Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations Nat. Genet. 2018 50 1219 1224 10.1038/s41588-018-0183-z 30104762 PMC6128408 Khera, A. V. et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat. Genet. 50 30104762 10.1038/s41588-018-0183-z PMC6128408 4. Frieser MJ Wilson S Vrieze SI Behavioral impact of return of genetic test results for complex disease: systematic review and meta-analysis Health Psychol. 2018 37 1134 1144 10.1037/hea0000683 30307272 PMC6263735 Frieser, M. J., Wilson, S. & Vrieze, S. I. Behavioral impact of return of genetic test results for complex disease: systematic review and meta-analysis. Health Psychol. 37 30307272 10.1037/hea0000683 PMC6263735 5. Natarajan P Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting Circulation 2017 135 2091 2101 10.1161/CIRCULATIONAHA.116.024436 28223407 PMC5484076 Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135 28223407 10.1161/CIRCULATIONAHA.116.024436 PMC5484076 6. Mahajan A Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation Nat. Genet. 2022 54 560 572 10.1038/s41588-022-01058-3 35551307 PMC9179018 Mahajan, A. et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54 35551307 10.1038/s41588-022-01058-3 PMC9179018 7. Vujkovic M Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis Nat. Genet. 2020 52 680 691 10.1038/s41588-020-0637-y 32541925 PMC7343592 Vujkovic, M. et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat. Genet. 52 32541925 10.1038/s41588-020-0637-y PMC7343592 8. Polfus LM Genetic discovery and risk characterization in type 2 diabetes across diverse populations Hum. Genet. Genom. Adv. 2021 2 100029 10.1016/j.xhgg.2021.100029 PMC8486151 34604815 Polfus, L. M. et al. Genetic discovery and risk characterization in type 2 diabetes across diverse populations. Hum. Genet. Genom. Adv. 2 10.1016/j.xhgg.2021.100029 PMC8486151 34604815 9. Langenberg C Gene–lifestyle interaction and type 2 diabetes: the EPIC InterAct Case-Cohort study PLoS Med. 2014 11 e1001647 10.1371/journal.pmed.1001647 24845081 PMC4028183 Langenberg, C. et al. Gene–lifestyle interaction and type 2 diabetes: the EPIC InterAct Case-Cohort study. PLoS Med. 11 24845081 10.1371/journal.pmed.1001647 PMC4028183 10. Wu P Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose PLoS ONE 2020 15 e0230815 10.1371/journal.pone.0230815 32379818 PMC7205201 Wu, P. et al. Smoking-by-genotype interaction in type 2 diabetes risk and fasting glucose. PLoS ONE 15 32379818 10.1371/journal.pone.0230815 PMC7205201 11. Dietrich S Gene-lifestyle interaction on risk of type 2 diabetes: a systematic review Obes. Rev. 2019 20 1557 1571 10.1111/obr.12921 31478326 PMC8650574 Dietrich, S. et al. Gene-lifestyle interaction on risk of type 2 diabetes: a systematic review. Obes. Rev. 20 31478326 10.1111/obr.12921 PMC8650574 12. Ruan Y Improving polygenic prediction in ancestrally diverse populations Nat. Genet. 2022 54 573 580 10.1038/s41588-022-01054-7 35513724 PMC9117455 Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. Nat. Genet. 54 35513724 10.1038/s41588-022-01054-7 PMC9117455 13. Darst BF Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry Am. J. Hum. Genet. 2023 110 1200 1206 10.1016/j.ajhg.2023.05.010 37311464 PMC10357473 Darst, B. F. et al. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am. J. Hum. Genet. 110 37311464 10.1016/j.ajhg.2023.05.010 PMC10357473 14. Gunn S Comparison of methods for building polygenic scores for diverse populations Hum. Genet. Genom. Adv. 2025 6 100355 10.1016/j.xhgg.2024.100355 PMC11532986 39323095 Gunn, S. et al. Comparison of methods for building polygenic scores for diverse populations. Hum. Genet. Genom. Adv. 6 10.1016/j.xhgg.2024.100355 PMC11532986 39323095 15. Wang Y Polygenic prediction across populations is influenced by ancestry, genetic architecture, and methodology Cell Genom. 2023 3 100408 10.1016/j.xgen.2023.100408 37868036 PMC10589629 Wang, Y. et al. Polygenic prediction across populations is influenced by ancestry, genetic architecture, and methodology. Cell Genom. 3 37868036 10.1016/j.xgen.2023.100408 PMC10589629 16. Ge T Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations Genome Med. 2022 14 70 10.1186/s13073-022-01074-2 35765100 PMC9241245 Ge, T. et al. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations. Genome Med. 14 35765100 10.1186/s13073-022-01074-2 PMC9241245 17. Ng MCY Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes PLoS Genet. 2014 10 e1004517 10.1371/journal.pgen.1004517 25102180 PMC4125087 Ng, M. C. Y. et al. Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. PLoS Genet. 10 25102180 10.1371/journal.pgen.1004517 PMC4125087 18. Sakaue S A cross-population atlas of genetic associations for 220 human phenotypes Nat. Genet. 2021 53 1415 1424 10.1038/s41588-021-00931-x 34594039 PMC12208603 Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53 34594039 10.1038/s41588-021-00931-x PMC12208603 19. Mahajan A Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps Nat. Genet. 2018 50 1505 1513 10.1038/s41588-018-0241-6 30297969 PMC6287706 Mahajan, A. et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat. Genet. 50 30297969 10.1038/s41588-018-0241-6 PMC6287706 20. Kachuri L Principles and methods for transferring polygenic risk scores across global populations Nat. Rev. Genet. 2024 25 8 25 10.1038/s41576-023-00637-2 37620596 PMC10961971 Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. Nat. Rev. Genet. 25 37620596 10.1038/s41576-023-00637-2 PMC10961971 21. Wang MC Shah NS Carnethon MR O’Brien MJ Khan SS Age at diagnosis of diabetes by race and ethnicity in the United States from 2011 to 2018 JAMA Intern. Med. 2021 181 1537 1539 10.1001/jamainternmed.2021.4945 34491260 PMC8424523 Wang, M. C., Shah, N. S., Carnethon, M. R., O’Brien, M. J. & Khan, S. S. Age at diagnosis of diabetes by race and ethnicity in the United States from 2011 to 2018. JAMA Intern. Med. 181 34491260 10.1001/jamainternmed.2021.4945 PMC8424523 22. de Miguel-Yanes JM Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms Diabetes Care 2011 34 121 125 10.2337/dc10-1265 20889853 PMC3005447 de Miguel-Yanes, J. M. et al. Genetic risk reclassification for type 2 diabetes by age below or above 50 years using 40 type 2 diabetes risk single nucleotide polymorphisms. Diabetes Care 34 20889853 10.2337/dc10-1265 PMC3005447 23. Chen F Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations eLife 2022 11 e78304 10.7554/eLife.78304 35801699 PMC9322982 Chen, F. et al. Validation of a multi-ancestry polygenic risk score and age-specific risks of prostate cancer: a meta-analysis within diverse populations. eLife 11 35801699 10.7554/eLife.78304 PMC9322982 24. Conti DV Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction Nat. Genet. 2021 53 65 75 10.1038/s41588-020-00748-0 33398198 PMC8148035 Conti, D. V. et al. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat. Genet. 53 33398198 10.1038/s41588-020-00748-0 PMC8148035 25. Schaid DJ Sinnwell JP Batzler A McDonnell SK Polygenic risk for prostate cancer: Decreasing relative risk with age but little impact on absolute risk Am. J. Hum. Genet. 2022 109 900 908 10.1016/j.ajhg.2022.03.008 35353984 PMC9118111 Schaid, D. J., Sinnwell, J. P., Batzler, A. & McDonnell, S. K. Polygenic risk for prostate cancer: Decreasing relative risk with age but little impact on absolute risk. Am. J. Hum. Genet. 109 35353984 10.1016/j.ajhg.2022.03.008 PMC9118111 26. Archambault AN Cumulative burden of colorectal cancer-associated genetic variants is more strongly associated with early-onset vs. late-onset cancer Gastroenterology 2020 158 1274 1286.e12. 10.1053/j.gastro.2019.12.012 31866242 PMC7103489 Archambault, A. N. et al. Cumulative burden of colorectal cancer-associated genetic variants is more strongly associated with early-onset vs. late-onset cancer. Gastroenterology 158 31866242 10.1053/j.gastro.2019.12.012 PMC7103489 27. Thomas M Genome-wide modeling of polygenic risk score in colorectal cancer risk Am. J. Hum. Genet. 2020 107 432 444 10.1016/j.ajhg.2020.07.006 32758450 PMC7477007 Thomas, M. et al. Genome-wide modeling of polygenic risk score in colorectal cancer risk. Am. J. Hum. Genet. 107 32758450 10.1016/j.ajhg.2020.07.006 PMC7477007 28. Mavaddat N Polygenic risk scores for prediction of breast cancer and breast cancer subtypes Am. J. Hum. Genet. 2019 104 21 34 10.1016/j.ajhg.2018.11.002 30554720 PMC6323553 Mavaddat, N. et al. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes. Am. J. Hum. Genet. 104 30554720 10.1016/j.ajhg.2018.11.002 PMC6323553 29. Marston NA Predictive utility of a coronary artery disease polygenic risk score in primary prevention JAMA Cardiol. 2023 8 130 137 10.1001/jamacardio.2022.4466 36576811 PMC9857431 Marston, N. A. et al. Predictive utility of a coronary artery disease polygenic risk score in primary prevention. JAMA Cardiol. 8 36576811 10.1001/jamacardio.2022.4466 PMC9857431 30. Ghatan S Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations Genome Med. 2024 16 10 10.1186/s13073-023-01255-7 38200577 PMC10777532 Ghatan, S. et al. Defining type 2 diabetes polygenic risk scores through colocalization and network-based clustering of metabolic trait genetic associations. Genome Med. 16 38200577 10.1186/s13073-023-01255-7 PMC10777532 31. Orozco G Ioannidis JP Morris A Zeggini E the DIAGRAM consortium. Sex-specific differences in effect size estimates at established complex trait loci Int. J. Epidemiol. 2012 41 1376 1382 10.1093/ije/dys104 22825589 PMC3465768 Orozco, G., Ioannidis, J. P., Morris, A., Zeggini, E. & the DIAGRAM consortium. Sex-specific differences in effect size estimates at established complex trait loci. Int. J. Epidemiol. 41 22825589 10.1093/ije/dys104 PMC3465768 32. Bernabeu E Sex differences in genetic architecture in the UK Biobank Nat. Genet. 2021 53 1283 1289 10.1038/s41588-021-00912-0 34493869 Bernabeu, E. et al. Sex differences in genetic architecture in the UK Biobank. Nat. Genet. 53 34493869 10.1038/s41588-021-00912-0 33. Feng Y Heritability estimation and environmental risk assessment for type 2 diabetes mellitus in a rural region in Henan, China: family-based and case-control studies Front. Public Health 2021 9 690889 10.3389/fpubh.2021.690889 34307284 PMC8295650 Feng, Y. et al. Heritability estimation and environmental risk assessment for type 2 diabetes mellitus in a rural region in Henan, China: family-based and case-control studies. Front. Public Health 9 34307284 10.3389/fpubh.2021.690889 PMC8295650 34. Ge T Chen CY Neale BM Sabuncu MR Smoller JW Phenome-wide heritability analysis of the UK Biobank PLoS Genet. 2017 13 e1006711 10.1371/journal.pgen.1006711 28388634 PMC5400281 Ge, T., Chen, C. Y., Neale, B. M., Sabuncu, M. R. & Smoller, J. W. Phenome-wide heritability analysis of the UK Biobank. PLoS Genet. 13 28388634 10.1371/journal.pgen.1006711 PMC5400281 35. Zillikens MC Sex-specific genetic effects influence variation in body composition Diabetologia 2008 51 2233 2241 10.1007/s00125-008-1163-0 18839131 Zillikens, M. C. et al. Sex-specific genetic effects influence variation in body composition. Diabetologia 51 18839131 10.1007/s00125-008-1163-0 36. Mostafavi, H. et al. Variable prediction accuracy of polygenic scores within an ancestry group. eLife 9 10.7554/eLife.48376 PMC7067566 31999256 37. Hou, K. et al. Calibrated prediction intervals for polygenic scores across diverse contexts. Nat. Genet 10.1038/s41588-024-01792-w PMC11465192 38886587 38. Hui, D. et al. Risk factors affecting polygenic score performance across diverse cohorts. eLife 12 10.7554/eLife.88149 PMC11771958 39851248 39. Berumen J Sex differences in the influence of type 2 diabetes (T2D)-related genes, parental history of T2D, and obesity on T2D development: a case–control study Biol. Sex. Differ. 2023 14 39 10.1186/s13293-023-00521-y 37291636 PMC10251612 Berumen, J. et al. Sex differences in the influence of type 2 diabetes (T2D)-related genes, parental history of T2D, and obesity on T2D development: a case–control study. Biol. Sex. Differ. 14 37291636 10.1186/s13293-023-00521-y PMC10251612 40. Lagou V Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability Nat. Commun. 2021 12 24 10.1038/s41467-020-19366-9 33402679 PMC7785747 Lagou, V. et al. Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nat. Commun. 12 33402679 10.1038/s41467-020-19366-9 PMC7785747 41. Kautzky-Willer A Harreiter J Pacini G Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus Endocr. Rev. 2016 37 278 316 10.1210/er.2015-1137 27159875 PMC4890267 Kautzky-Willer, A., Harreiter, J. & Pacini, G. Sex and gender differences in risk, pathophysiology and complications of type 2 diabetes mellitus. Endocr. Rev. 37 27159875 10.1210/er.2015-1137 PMC4890267 42. Varlamov O Bethea CL Roberts CT Sex-specific differences in lipid and glucose metabolism Front. Endocrinol. 2015 5 241 10.3389/fendo.2014.00241 PMC4298229 25646091 Varlamov, O., Bethea, C. L. & Roberts, C. T. Sex-specific differences in lipid and glucose metabolism. Front. Endocrinol. 5 10.3389/fendo.2014.00241 PMC4298229 25646091 43. Lee J Kim MH Jang JY Oh CM Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study Clin. Diabetes Endocrinol. 2023 9 7 10.1186/s40842-023-00156-3 37974292 PMC10652621 Lee, J., Kim, M. H., Jang, J. Y. & Oh, C. M. Assessment HOMA as a predictor for new onset diabetes mellitus and diabetic complications in non-diabetic adults: a KoGES prospective cohort study. Clin. Diabetes Endocrinol. 9 37974292 10.1186/s40842-023-00156-3 PMC10652621 44. Liedtke TP Characterizing trajectories of diabetes-related health parameters before diabetes diagnosis in diabetes subtypes: analysis of a 20-year long prospective cohort study in Sweden Cardiovasc. Diabetol. 2025 24 244 10.1186/s12933-025-02786-6 40490745 PMC12150535 Liedtke, T. P. et al. Characterizing trajectories of diabetes-related health parameters before diabetes diagnosis in diabetes subtypes: analysis of a 20-year long prospective cohort study in Sweden. Cardiovasc. Diabetol. 24 40490745 10.1186/s12933-025-02786-6 PMC12150535 45. Ruijgrok C Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study Diabetologia 2018 61 93 100 10.1007/s00125-017-4452-7 29018885 PMC6448924 Ruijgrok, C. et al. Size and shape of the associations of glucose, HbA1c, insulin and HOMA-IR with incident type 2 diabetes: the Hoorn Study. Diabetologia 61 29018885 10.1007/s00125-017-4452-7 PMC6448924 46. Tremblay J Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control Diabetologia 2021 64 2012 2025 10.1007/s00125-021-05491-7 34226943 PMC8382653 Tremblay, J. et al. Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. Diabetologia 64 34226943 10.1007/s00125-021-05491-7 PMC8382653 47. Yun JS Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study Cardiovasc. Diabetol. 2022 21 131 10.1186/s12933-022-01560-2 35836215 PMC9284808 Yun, J. S. et al. Polygenic risk for type 2 diabetes, lifestyle, metabolic health, and cardiovascular disease: a prospective UK Biobank study. Cardiovasc. Diabetol. 21 35836215 10.1186/s12933-022-01560-2 PMC9284808 48. Shoaib M Evaluation of polygenic risk scores to differentiate between type 1 and type 2 diabetes Genet. Epidemiol. 2023 47 303 313 10.1002/gepi.22521 36821788 PMC10202843 Shoaib, M. et al. Evaluation of polygenic risk scores to differentiate between type 1 and type 2 diabetes. Genet. Epidemiol. 47 36821788 10.1002/gepi.22521 PMC10202843 49. Matise TC The next PAGE in understanding complex traits: design for the analysis of population architecture using genetics and epidemiology (PAGE) study Am. J. Epidemiol. 2011 174 849 859 10.1093/aje/kwr160 21836165 PMC3176830 Matise, T. C. et al. The next PAGE in understanding complex traits: design for the analysis of population architecture using genetics and epidemiology (PAGE) study. Am. J. Epidemiol. 174 21836165 10.1093/aje/kwr160 PMC3176830 50. Wright JD The ARIC (Atherosclerosis Risk In Communities) study: JACC focus seminar 3/8 J. Am. Coll. Cardiol. 2021 77 2939 2959 10.1016/j.jacc.2021.04.035 34112321 PMC8667593 Wright, J. D. et al. The ARIC (Atherosclerosis Risk In Communities) study: JACC focus seminar 3/8. J. Am. Coll. Cardiol. 77 34112321 10.1016/j.jacc.2021.04.035 PMC8667593 51. Friedman GD Cardia: study design, recruitment, and some characteristics of the examined subjects J. Clin. Epidemiol. 1988 41 1105 1116 10.1016/0895-4356(88)90080-7 3204420 Friedman, G. D. et al. Cardia: study design, recruitment, and some characteristics of the examined subjects. J. Clin. Epidemiol. 41 3204420 10.1016/0895-4356(88)90080-7 52. Sorlie PD Design and implementation of the Hispanic Community Health Study/Study of Latinos Ann. Epidemiol. 2010 20 629 641 10.1016/j.annepidem.2010.03.015 20609343 PMC2904957 Sorlie, P. D. et al. Design and implementation of the Hispanic Community Health Study/Study of Latinos. Ann. Epidemiol. 20 20609343 10.1016/j.annepidem.2010.03.015 PMC2904957 53. LaVange LM Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos Ann. Epidemiol. 2010 20 642 649 10.1016/j.annepidem.2010.05.006 20609344 PMC2921622 LaVange, L. M. et al. Sample design and cohort selection in the Hispanic Community Health Study/Study of Latinos. Ann. Epidemiol. 20 20609344 10.1016/j.annepidem.2010.05.006 PMC2921622 54. Kolonel LN A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics Am. J. Epidemiol. 2000 151 346 357 10.1093/oxfordjournals.aje.a010213 10695593 PMC4482109 Kolonel, L. N. et al. A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am. J. Epidemiol. 151 10695593 10.1093/oxfordjournals.aje.a010213 PMC4482109 55. Anderson G Design of the Women’s Health Initiative clinical trial and observational study Control. Clin. Trials 1998 19 61 109 10.1016/S0197-2456(97)00078-0 9492970 Anderson, G. et al. Design of the Women’s Health Initiative clinical trial and observational study. Control. Clin. Trials 19 9492970 10.1016/s0197-2456(97)00078-0 56. All of Us Research Program Investigators The “All of Us” research program N. Engl. J. Med. 2019 381 668 676 10.1056/NEJMsr1809937 31412182 PMC8291101 All of Us Research Program Investigators et al. The “All of Us” research program. N. Engl. J. Med. 381 31412182 10.1056/NEJMsr1809937 PMC8291101 57. Roden D Development of a large-scale de-identified DNA Biobank to enable personalized medicine Clin. Pharm. Ther. 2008 84 362 369 10.1038/clpt.2008.89 PMC3763939 18500243 Roden, D. et al. Development of a large-scale de-identified DNA Biobank to enable personalized medicine. Clin. Pharm. Ther. 84 10.1038/clpt.2008.89 PMC3763939 18500243 58. Fisher-Hoch SP Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004–2007 Prev. Chronic Dis. 2010 7 A53 20394692 PMC2879985 Fisher-Hoch, S. P. et al. Socioeconomic status and prevalence of obesity and diabetes in a Mexican American community, Cameron County, Texas, 2004–2007. Prev. Chronic Dis. 7 20394692 PMC2879985 59. Adair LS Cohort profile: the Cebu longitudinal health and nutrition survey Int. J. Epidemiol. 2011 40 619 625 10.1093/ije/dyq085 20507864 PMC3147061 Adair, L. S. et al. Cohort profile: the Cebu longitudinal health and nutrition survey. Int. J. Epidemiol. 40 20507864 10.1093/ije/dyq085 PMC3147061 60. Popkin BM Du S Zhai F Zhang B Cohort Profile: the China Health and Nutrition Survey—monitoring and understanding socio-economic and health change in China, 1989–2011 Int. J. Epidemiol. 2010 39 1435 1440 10.1093/ije/dyp322 19887509 PMC2992625 Popkin, B. M., Du, S., Zhai, F. & Zhang, B. Cohort Profile: the China Health and Nutrition Survey—monitoring and understanding socio-economic and health change in China, 1989–2011. Int. J. Epidemiol. 39 19887509 10.1093/ije/dyp322 PMC2992625 61. Wiley LK Building a vertically integrated genomic learning health system: the biobank at the Colorado Center for Personalized Medicine Am. J. Hum. Genet. 2024 111 11 23 10.1016/j.ajhg.2023.12.001 38181729 PMC10806731 Wiley, L. K. et al. Building a vertically integrated genomic learning health system: the biobank at the Colorado Center for Personalized Medicine. Am. J. Hum. Genet. 111 38181729 10.1016/j.ajhg.2023.12.001 PMC10806731 62. Bjerregaard P Inuit health in Greenland: a population survey of life style and disease in Greenland and among Inuit living in Denmark Int. J. Circumpolar Health 2003 62 Suppl. 1 3 79 14527126 10.3402/ijch.v62i0.18212 Bjerregaard, P., et al. Inuit health in Greenland: a population survey of life style and disease in Greenland and among Inuit living in Denmark. Int. J. Circumpolar Health 62 14527126 10.3402/ijch.v62i0.18212 63. Moltke I Uncovering the genetic history of the present-day Greenlandic population Am. J. Hum. Genet. 2015 96 54 69 10.1016/j.ajhg.2014.11.012 25557782 PMC4289681 Moltke, I. et al. Uncovering the genetic history of the present-day Greenlandic population. Am. J. Hum. Genet. 96 25557782 10.1016/j.ajhg.2014.11.012 PMC4289681 64. Stæger FF Genetic architecture in Greenland is shaped by demography, structure and selection Nature 2025 12 1 7 10.1038/s41586-024-08516-4 PMC11903302 39939757 Stæger, F. F. et al. Genetic architecture in Greenland is shaped by demography, structure and selection. Nature 12 10.1038/s41586-024-08516-4 PMC11903302 39939757 65. Bild DE Multi-ethnic study of atherosclerosis: objectives and design Am. J. Epidemiol. 2002 156 871 881 10.1093/aje/kwf113 12397006 Bild, D. E. et al. Multi-ethnic study of atherosclerosis: objectives and design. Am. J. Epidemiol. 156 12397006 10.1093/aje/kwf113 66. Zawistowski M The Michigan Genomics Initiative: a biobank linking genotypes and electronic clinical records in Michigan Medicine patients Cell Genom. 2023 3 100257 10.1016/j.xgen.2023.100257 36819667 PMC9932985 Zawistowski, M. et al. The Michigan Genomics Initiative: a biobank linking genotypes and electronic clinical records in Michigan Medicine patients. Cell Genom. 3 36819667 10.1016/j.xgen.2023.100257 PMC9932985 67. Gaziano JM Million Veteran Program: a mega-biobank to study genetic influences on health and disease J. Clin. Epidemiol. 2016 70 214 223 10.1016/j.jclinepi.2015.09.016 26441289 Gaziano, J. M. et al. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70 26441289 10.1016/j.jclinepi.2015.09.016 68. Hunter-Zinck H Genotyping array design and data quality control in the Million Veteran Program Am. J. Hum. Genet. 2020 106 535 548 10.1016/j.ajhg.2020.03.004 32243820 PMC7118558 Hunter-Zinck, H. et al. Genotyping array design and data quality control in the Million Veteran Program. Am. J. Hum. Genet. 106 32243820 10.1016/j.ajhg.2020.03.004 PMC7118558 69. Taliun D Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program Nature 2021 590 290 299 10.1038/s41586-021-03205-y 33568819 PMC7875770 Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590 33568819 10.1038/s41586-021-03205-y PMC7875770 70. Al Kuwari H The Qatar Biobank: background and methods BMC Public Health 2015 15 1208 10.1186/s12889-015-2522-7 26635005 PMC4669623 Al Kuwari, H. et al. The Qatar Biobank: background and methods. BMC Public Health 15 26635005 10.1186/s12889-015-2522-7 PMC4669623 71. Howard VJ The reasons for geographic and racial differences in stroke study: objectives and design Neuroepidemiology 2005 25 135 143 10.1159/000086678 15990444 Howard, V. J. et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25 15990444 10.1159/000086678 72. Committee on the Use of Race, Ethnicity, and Ancestry as Population Descriptors in Genomics Research, Board on Health Sciences Policy, Committee on Population, Health and Medicine Division, Division of Behavioral and Social Sciences and Education, National Academies of Sciences, Engineering, and Medicine. Using Population Descriptors in Genetics and Genomics Research: A New Framework for an Evolving Field 36989389 73. Association A. D. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2021. Diabetes Care 10.2337/dc21-S002 33298413 74. Wojcik GL Genetic analyses of diverse populations improves discovery for complex traits Nature 2019 570 514 518 10.1038/s41586-019-1310-4 31217584 PMC6785182 Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for complex traits. Nature 570 31217584 10.1038/s41586-019-1310-4 PMC6785182 75. Das S Next-generation genotype imputation service and methods Nat. Genet. 2016 48 1284 1287 10.1038/ng.3656 27571263 PMC5157836 Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48 27571263 10.1038/ng.3656 PMC5157836 76. Fuchsberger C Abecasis GR Hinds DA minimac2: faster genotype imputation Bioinformatics 2015 31 782 784 10.1093/bioinformatics/btu704 25338720 PMC4341061 Fuchsberger, C., Abecasis, G. R. & Hinds, D. A. minimac2: faster genotype imputation. Bioinformatics 31 25338720 10.1093/bioinformatics/btu704 PMC4341061 77. Patterson N Price AL Reich D Population structure and eigenanalysis PLoS Genet. 2006 2 e190 10.1371/journal.pgen.0020190 17194218 PMC1713260 Patterson, N., Price, A. L. & Reich, D. Population structure and eigenanalysis. PLoS Genet. 2 17194218 10.1371/journal.pgen.0020190 PMC1713260 78. Price AL Principal components analysis corrects for stratification in genome-wide association studies Nat. Genet. 2006 38 904 909 10.1038/ng1847 16862161 Price, A. L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38 16862161 10.1038/ng1847 79. Buyske S Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study PLoS ONE 2012 7 e35651 10.1371/journal.pone.0035651 22539988 PMC3335090 Buyske, S. et al. Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. PLoS ONE 7 22539988 10.1371/journal.pone.0035651 PMC3335090 80. Chang CC Second-generation PLINK: rising to the challenge of larger and richer datasets GigaScience 2015 4 s13742-015-0047-0048 10.1186/s13742-015-0047-8 PMC4342193 25722852 Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience 4 10.1186/s13742-015-0047-8 PMC4342193 25722852 81. Lawrence M Gentleman R Carey V rtracklayer: an R package for interfacing with genome browsers Bioinformatics 2009 25 1841 1842 10.1093/bioinformatics/btp328 19468054 PMC2705236 Lawrence, M., Gentleman, R. & Carey, V. rtracklayer: an R package for interfacing with genome browsers. Bioinformatics 25 19468054 10.1093/bioinformatics/btp328 PMC2705236 82. Sheng X Inverted genomic regions between reference genome builds in humans impact imputation accuracy and decrease the power of association testing Hum. Genet. Genom. Adv. 2023 4 100159 10.1016/j.xhgg.2022.100159 PMC9709082 36465187 Sheng, X. et al. Inverted genomic regions between reference genome builds in humans impact imputation accuracy and decrease the power of association testing. Hum. Genet. Genom. Adv. 4 10.1016/j.xhgg.2022.100159 PMC9709082 36465187 83. Robin X pROC: an open-source package for R and S+ to analyze and compare ROC curves BMC Bioinform. 2011 12 77 10.1186/1471-2105-12-77 PMC3068975 21414208 Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinform. 12 10.1186/1471-2105-12-77 PMC3068975 21414208 84. Carroll RJ Bastarache L Denny JC R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment Bioinformatics 2014 30 2375 2376 10.1093/bioinformatics/btu197 24733291 PMC4133579 Carroll, R. J., Bastarache, L. & Denny, J. C. R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment. Bioinformatics 30 24733291 10.1093/bioinformatics/btu197 PMC4133579 ",
  "metadata": {
    "Title of this paper": "R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment",
    "Journal it was published in:": "Nature Communications",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12488948/"
  }
}